| 1. |
|
|
| 2. |
- Ingvarsson, Johan, et al.
(författare)
-
Detection of pancreatic cancer using antibody microarray-based serum protein profiling
- 2008
-
Ingår i: Proteomics. - : Wiley. - 1615-9861 .- 1615-9853. ; 8:11, s. 2211-2219
-
Tidskriftsartikel (refereegranskat)abstract
- The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of <12 months. Taken together, the data suggest that antibody microarray analysis of complex proteomes will be a useful tool to define disease associated protein signatures.
|
|
| 3. |
|
|
| 4. |
- Knaust, Eva, 1944-
(författare)
-
Experimental studies on multidrug resistance in human leukaemia : role of cellular heterogeneity for daunorubicin kinetics
- 2005
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Cellular resistance to chemotherapy is a major cause of treatment failure in acute myeloid leukaemia (AML) and still the majority of the patients die from their disease. Drug resistance 1s multifactorial, the most studied mechanism being multidrug resistance (MDR), mediated by the P-glycoprotein (Pgp). Pgp is an energy-dependent transport protein, encoded by the mdr1 gene, with the power to extrude the cytotoxic drugs out of the cells; thus causing reduced effect of the drug on the leukaemic cells. MDR is characterised by cross-resistance to a wide range of chemotherapeutics of natural origin. Other transport proteins, involved in drug resistance, are the multidrug resistance associated protein (MRP) and the lung resistance protein (Lrp).The aims of this thesis were to elucidate transport kinetics of the anthracycline, daunorubicin, (Dnr) and to investigate the effects of reversing agents on heterogeneity of drug accumulation in cells from patients with AML. The ultimate goal is to improve treatment based on each patient's individual resistance patterns.Density gradient isolated mononuclear cells from patients with AML were incubated with Dnr. Incubated cells were sorted with flow cytometry (FC) on the basis of accumulation levels of the autofluorescent Dnr. Gene expression of the Pgp and the MRP in sorted subpopulations were analysed with polymerase chain reaction (PCR). Apoptosis, expression of p53 and bcl-2 in the sorted subpopulations were determined with monoclonal antibodies and FC. Drug accumulation and efflux, with/without the resistance modifier Cyclosporin A (CyA) and energy-depleting metabolic inhibitors (MJ), were also determined in the leukaemic cell populations with FC.Gene expressions of mdr1 and mrp1 were shown to be heterogeneous in the leukaemic samples and drug accumulation correlated inversely to the gene expression. Cell populations with the higher drug accumulation entailed more apoptosis. The leukaemic cell lopulation, defined by immunopenotyping, differed in drug accumulation an efflux compared to the total mononuclear cell population that also contains normal lymphocytes and monocytes. In leukaemic samples with two blast cell populations, the more immature blast ceUs accumulated drug to a lesser extent and bad a higher efflux rate than the differentiating blast cells. CyA reduced Dnr efflux more efficiently than MI, but MJ increased drug accumulation in leukaemic cells more than CyA.In conclusion: analysis of the total mononuclear population does not give an accurate picture of the leukaemic cell population as concerns resistance mechanisms. Heterogeneity in the leukaemic cell population ought to be taken into account since two or more leukaemic cell populations often exist. The most immature blast cell population should be analysed as relapse usually derives from this population. Furthermore the role of Pgp in MDR is not conclusive as results with reversing agents differed from what was expected.
|
|
| 5. |
- Lettesjö, Helene, 2000, et al.
(författare)
-
Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis.
- 2006
-
Ingår i: Scandinavian journal of gastroenterology. - : Informa UK Limited. - 0036-5521 .- 1502-7708. ; 41:1, s. 54-9
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: Irritable bowel syndrome (IBS) and collagenous colitis (CC) share chronically recurring symptoms of altered bowel habits associated with abdominal pain or discomfort. The aims of the present study were to investigate whether inflammatory markers could be detected in faeces from patients with IBS and CC, and to elucidate whether such analyses could be used as non-invasive tools to distinguish between these disorders. MATERIAL AND METHODS: Stool samples were obtained from 18 patients with CC, 46 patients with IBS and 20 healthy controls (HC). Eosinophil protein X (EPX), myeloperoxidase (MPO), tryptase, interleukin-1 beta (IL-1beta) and tumour necrosis factor alpha (TNFalpha) were measured in supernatants from processed faeces using immunoassays. RESULTS: EPX levels were enhanced in faeces from CC patients (median 3.8 microg/g (0.47-16.2)) compared to patients with IBS (0.44 microg/g (0.25-1.8)), p<0.001, and HC (0.46 microg/g (0.21-1.3)), p<0.001. In addition, MPO was increased in CC patients (11.7 microg/g (2.0-124)) compared to IBS patients (1.7 microg/g (0.81-5.2)), p<0.01, and HC (2.5 microg/g (1.1-6.3)), p<0.05. Tryptase was found in 9/18 patients with CC, 6/46 with IBS and 1/19 HC. IL-1beta was only enhanced in 2/11 CC patients and TNFalpha was not detected in any sample. CONCLUSIONS: Increased levels of EPX, MPO and tryptase were observed in stools from collagenous colitis patients, whereas the levels in IBS patients did not differ from healthy controls. Our data suggest that faecal markers could be used as part of the clinical work-up to determine which patients should be biopsied and evaluated for collagenous colitis.
|
|
| 6. |
|
|
| 7. |
- Lilja, Kari, et al.
(författare)
-
Mobilising transnational epistemic communities in a multi-level system of innovation : the case of the forest based sector technology platform
- 2007
-
Konferensbidrag (refereegranskat)abstract
- The national innovation systems have been complemented with R&D programmes at the EU level. As part of the 7th Framework Program, the EU has adopted a new policy making tool, called Technology Platforms (TP). The purpose of the paper is to narrate a story of one TP, that of the Forest Based Sector Technology Platform (FTP), and to speculate on its potential consequences. The story of the emergence of the FTP concentrates on the role of institutional entrepreneurs that have been able to orchestrate a transnational mobilisation process. The emerging debate has also made visible gaps in national and transnational modes of operating. Despite the identified gaps there are signs that a Nordic innovation system is emerging in the forest sector with strong organisational linkages to all EU countries. By a Nordic innovation system we mean in this specific sectoral context that collaboration in R&D is not only based on long-term collaborative projects of buyers and sellers of new technological processes but on the a long term commitment of core institutional entrepreneurs to a variety of parallel research programmes at the transnational level. This is backed up by transnational operations and ownership structures of core private Nordic-based R&D organisations. Thus the early steps of a fieldwork based research project on the FTP give new insights of the interrelations of national and transnational R&D policies and the ways in which EU´s attempts to introduce experimentalist forms of decentralised governance stimulate integration of national innovation systems at the transnational level.
|
|
| 8. |
- Lilja, Kari, et al.
(författare)
-
The case of the forest-based sector technology platform
- 2008
-
Ingår i: Paperi ja puu. - 0031-1243. ; 90:2, s. 29-33
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The forest sector has taken significant steps at the European level to improve its engagement in large-scale European-wide research programmes. As part of the preparation of the 7th Framework Program, the forest sector made use of a new research policy tool, called Technology Platform (TP). This tool was launched by the European Union (EU) to get companies, industries, and sectors to become more involved in the funding and implementing of research programmes in cooperation with universities and research institutes.
|
|
| 9. |
- Nielsen, Lars Peter, et al.
(författare)
-
Serum eosinophil granule proteins predict asthma risk in allergic rhinitis
- 2009
-
Ingår i: Allergy. European Journal of Allergy and Clinical Immunology. - : Wiley. - 0105-4538 .- 1398-9995. ; 64:5, s. 733-737
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Allergic rhinitis is a common disease, in which some patients will deteriorate or develop asthma. It is important to characterize these patients, thereby offering the possibility for prevention. This study evaluated eosinophil parameters as potential indicators of deteriorating allergic airway disease. Methods: The subjects of the study included all patients who suffered seasonal allergic rhinitis and had participated in a study 6 years earlier, in which blood eosinophils, serum eosinophil cationic protein (ECP) serum eosinophil peroxidase (EPO), nasal lavage ECP and nasal lavage EPO levels were measured. Patients in the present study were interviewed on occurrence of rhinitis symptoms during the last season, rhinitis outside season, asthma-like symptoms and asthma diagnosis, and were skin-prick tested for common aeroallergens. Eosinophil parameters from the study 6 years earlier were then tested for the ability to predict occurrence of new allergies, worsening of rhinitis and occurrence of asthma. Results: Forty-four patients participated in the study. In four patients seasonal rhinitis symptoms had deteriorated, 10 had experienced perennial rhinitis symptoms, 14 reported asthma-like symptoms and seven had been diagnosed with asthma. Thirteen had developed additional sensitization. Patients developing asthma-like symptoms compared with patients with no such symptoms had significantly higher serum ECP (16.7 lg/l vs 8.2 lg/l; P £ 0.01) and serum EPO (17.9 lg/l vs 8.8 lg/l; P £ 0.05). Results were similar, considering patients diagnosed with asthma. Blood eosinophils and nasal lavage parameters were not related to development of asthma and asthma-like symptoms. No eosinophil parameter was related to deterioration of rhinitis or additional sensitization. Conclusion: Serum ECP and EPO in patients with seasonal rhinitis demonstrated a high predictive ability for later development of asthma.
|
|
| 10. |
|
|
